Study of Personalized Medicine and Behavior of different Marketed Drugs of CML

Authors

  • Vani Tirpathi
  • Shanti Sundaram
  • Rakesh Singh Rajput

DOI:

https://doi.org/10.37591/(rrjobi).v4i3.100

Abstract

Personalized medicine is rapidly developing practice of medicine that uses an individual's genetic profile to guide decisions made in regard to the prevention, diagnosis, and treatment of disease. CML (Chronic Myeloid Leukemia) is characterized by a Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22, containing a chimeric gene called BCR-ABL. Management of patients with chronic myeloid leukemia has become increasingly difficult over the last few years since there are a variety of treatment options available. The ultimate challenge is to decide the most appropriate treatment strategy for an individual patient. To facilitate this, assessment of an individual patient's disease in terms of status, tempo and response to initial treatment needs to be determined. Over here we had tried to study five different marketed drugs of leukemia and its effects.

 

Keywords: Isoforms, personalized medicine, CML, BCR-ABL

 

Cite this Article

Vani Tirpathi, Shanti Sundaram, Rakesh Singh Rajput. Study of Personalized Medicine and Behavior of different Marketed Drugs of CML. Research & Reviews: A Journal of Bioinformatics. 2017; 4(3): 34–38p.

Downloads

Additional Files

Published

2018-04-04

Issue

Vol. 4 No. 3 (2017)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.